HONG KONG, Nov. 16, 2021 /PRNewswire/ -- The Centurium Capital-led privatization of leading plasma-based biopharmaceutical company China Biologic Products Holdings Inc. ("China Biologic" or the "Company") was awarded "Deal of the Year – Large Cap" by Asia Venture Capital Journal (AVCJ) at its annual award ceremony on November 15 in Hong Kong. A buyer consortium led by Centurium Capital first announced its indicative proposal to privatize the Nasdaq-listed China Biologic (NASDAQ:CBPO) on September 18, 2019. On November 19, 2020, the two sides had reached an agreement for the consortium to purchase the outstanding shares not already owned by the consortium members at US$120 per share, implying

BEIJING, April 20, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ:CBPO, ", China Biologic", or the ", Company", ))), a leading fully integrated plasma-based biopharmaceutical company in China, today announced the completion of its merger (the "Merger") with CBPO Group Limited ("Merger Sub"), a wholly owned subsidiary of CBPO Holdings Limited ("Parent"), pursuant to the previously announced agreement and plan of merger, dated as of November 19, 2020 (the "Merger Agreement") among the Company, Parent and Merger Sub. As a result of the Merger, the Company became a wholly owned subsidiary of Parent and will cease to be a publicly traded company. Pursuant to the terms of the

BEIJING, March 29, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2020. Fourth Quarter 2020 Financial Highlights Total sales in the fourth quarter of 2020 increased by 9.7% in USD terms and 3.2% in RMB terms to $112.1 million from $102.2 million in the same quarter of 2019. Gross profit increased by 16.6% to $74.6 million from $64.0 million in the same quarter of 2019. Gross margin increased to 66.5% from 62.6% in the same quarter of 2019. Income from operations increased

BEIJING, March 1, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that, at an extraordinary general meeting (the "EGM") held today, the Company's shareholders voted in favor of the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of November 19, 2020 (the "Merger Agreement"), among the Company, CBPO Holdings Limited ("Parent") and CBPO Group Limited ("Merger Sub"), pursuant to which, Merger Sub will be merged with and into the Company with the Company continuing as the surviving company and

BEIJING, Jan. 25, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that it has called an extraordinary general meeting of shareholders (the "EGM") to be held on March 1, 2021 at 10:00 a.m. (Beijing time), at the principal office of the Company located at 18th Floor, Jialong International Building, 19 Chaoyang Park Road, Chaoyang District, Beijing, China, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of November 19, 2020 (the "Merger Agre

New York, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Plasma Fractionation: Global Markets" - https://www.reportlinker.com/p05993362/?utm_source=GNW The report also covers market projections through 2025, as well as key market players.This report details market shares for plasma fractionation based on product, application, end user and geography.Based on product, the market is segmented into immunoglobulins, albumins, coagulation factor concentrates and other segments.Based on application, the market is segmented into neurology, immunology, hematology and others. Based on end user, the market segmented into hospitals and clinics, research labora

15-12B - China Biologic Products Holdings, Inc. (0001369868) (Filer)

S-8 POS - China Biologic Products Holdings, Inc. (0001369868) (Filer)

S-8 POS - China Biologic Products Holdings, Inc. (0001369868) (Filer)

SC 13E3/A - China Biologic Products Holdings, Inc. (0001369868) (Subject)

6-K - China Biologic Products Holdings, Inc. (0001369868) (Filer)

25-NSE - China Biologic Products Holdings, Inc. (0001369868) (Subject)

6-K - China Biologic Products Holdings, Inc. (0001369868) (Filer)

6-K - China Biologic Products Holdings, Inc. (0001369868) (Filer)

6-K - China Biologic Products Holdings, Inc. (0001369868) (Filer)

SC 13E3/A - China Biologic Products Holdings, Inc. (0001369868) (Subject)

BEIJING, March 29, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2020. Fourth Quarter 2020 Financial Highlights Total sales in the fourth quarter of 2020 increased by 9.7% in USD terms and 3.2% in RMB terms to $112.1 million from $102.2 million in the same quarter of 2019. Gross profit increased by 16.6% to $74.6 million from $64.0 million in the same quarter of 2019. Gross margin increased to 66.5% from 62.6% in the same quarter of 2019. Income from operations increased

SC 13D/A - China Biologic Products Holdings, Inc. (0001369868) (Subject)

SC 13D/A - China Biologic Products Holdings, Inc. (0001369868) (Subject)

SC 13D/A - China Biologic Products Holdings, Inc. (0001369868) (Subject)

SC 13D/A - China Biologic Products Holdings, Inc. (0001369868) (Subject)

SC 13D/A - China Biologic Products Holdings, Inc. (0001369868) (Subject)

SC 13D/A - China Biologic Products Holdings, Inc. (0001369868) (Subject)